Emergent BioSolutions Inc (EBS):企業の財務・戦略的SWOT分析

◆英語タイトル:Emergent BioSolutions Inc (EBS) - Financial and Strategic SWOT Analysis Review
◆商品コード:GDPH6940FSA
◆発行会社(調査会社):GlobalData
◆発行日:2021年4月
◆ページ数:68
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:Pharmaceuticals and Healthcare
◆販売価格オプション(消費税別)
Site License(同一事業所内共有可)USD250 ⇒換算¥27,500見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD375 ⇒換算¥41,250見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Emergent BioSolutions Inc (EBS) – Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.
The profile contains critical company information including:

- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – Analyst’s summarization of the company’s business strategy.
- SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
- Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Emergent BioSolutions Inc (Emergent) is a life sciences company that provides solutions to address public health threats including chemical, biological, radiological, nuclear and explosives (CBRNE), emerging infectious diseases, travel health, emerging health crises and acute/emergency care. It offers vaccines, therapeutics, drug-device combination products and contract development and manufacturing services. Emergent has a developmental pipeline of candidates targeting dengue and other influenza infections. It also offers its specialized products to governments and commercial customers. The company distributes its products in the US and Canada through its commercial sales forces and third-party distributors. Emergent is headquartered in Rockville, Maryland, the US.

Emergent BioSolutions Inc Key Recent Developments

Mar 02,2021: Biden’s latest announcement about invoking DPA
Feb 18,2021: Emergent BioSolutions Reports Financial Results for Fourth Quarter and Full Year 2020
Feb 04,2021: Emergent BioSolutions to release fourth quarter and full year 2020 financial results and conduct a conference call on february 18, 2021
Jan 12,2021: Department of Justice issues positive business review letter to companies developing plasma therapies for Covid-19
Jan 10,2021: Emergent BioSolutions announces 2021 financial guidance, provides preliminary 2020 results

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
- The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

【レポートの目次】

Table of Contents
List of Tables
List of Figures
Section 1 – About the Company
Emergent BioSolutions Inc – Key Facts
Emergent BioSolutions Inc – Key Employees
Emergent BioSolutions Inc – Key Employee Biographies
Emergent BioSolutions Inc – Major Products and Services
Emergent BioSolutions Inc – History
Emergent BioSolutions Inc – Company Statement
Emergent BioSolutions Inc – Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Joint Venture
Section 2 – Company Analysis
Company Overview
Emergent BioSolutions Inc – Business Description
Business Segment: Contract Development and Manufacturing Services
Performance
Business Segment: Contracts and Grants
Performance
Business Segment: Product Sales
Performance
Emergent BioSolutions Inc – Corporate Strategy
Emergent BioSolutions Inc – SWOT Analysis
SWOT Analysis – Overview
Emergent BioSolutions Inc – Strengths
Emergent BioSolutions Inc – Weaknesses
Emergent BioSolutions Inc – Opportunities
Emergent BioSolutions Inc – Threats
Emergent BioSolutions Inc – Key Competitors
Section 3 – Company Financial Ratios
Financial Ratios – Capital Market Ratios
Financial Ratios – Annual Ratios
Performance Chart
Financial Performance
Financial Ratios – Interim Ratios
Financial Ratios – Ratio Charts
Section 4 – Company’s Lifesciences Financial Deals and Alliances
Emergent BioSolutions Inc, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
Emergent BioSolutions Inc, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021
Emergent BioSolutions Inc, Recent Deals Summary
Section 5 – Company’s Recent Developments
Mar 02, 2021: Biden’s latest announcement about invoking DPA
Feb 18, 2021: Emergent BioSolutions Reports Financial Results for Fourth Quarter and Full Year 2020
Feb 04, 2021: Emergent BioSolutions to release fourth quarter and full year 2020 financial results and conduct a conference call on february 18, 2021
Jan 12, 2021: Department of Justice issues positive business review letter to companies developing plasma therapies for Covid-19
Jan 10, 2021: Emergent BioSolutions announces 2021 financial guidance, provides preliminary 2020 results
Nov 05, 2020: Emergent BioSolutions reports financial results for third quarter and nine months ended September 30, 2020 and updates full year 2020 guidance
Sep 24, 2020: Emergent BioSolutions applauds Pharmacy Leaders on Consensus Guidelines for Naloxone
Aug 31, 2020: Emergent BioSolutions teams up with Boston Red Sox, Cincinnati Reds, Philadelphia Phillies, and MAPDA to highlight importance of overdose reversal medicines on International Overdose Awareness Day
Aug 26, 2020: Emergent BioSolutions announces appointment of Marvin White to the Company’s Board of Directors
Jul 30, 2020: Emergent BioSolutions reports financial results for second quarter and six months ended june 30, 2020 and revises upward full year 2020 guidance
Section 6 – Appendix
Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer

List of Tables
Emergent BioSolutions Inc, Key Facts
Emergent BioSolutions Inc, Key Employees
Emergent BioSolutions Inc, Key Employee Biographies
Emergent BioSolutions Inc, Major Products and Services
Emergent BioSolutions Inc, History
Emergent BioSolutions Inc, Other Locations
Emergent BioSolutions Inc, Subsidiaries
Emergent BioSolutions Inc, Joint Venture
Emergent BioSolutions Inc, Key Competitors
Emergent BioSolutions Inc, Ratios based on current share price
Emergent BioSolutions Inc, Annual Ratios
Emergent BioSolutions Inc, Annual Ratios (Cont...1)
Emergent BioSolutions Inc, Annual Ratios (Cont...2)
Emergent BioSolutions Inc, Interim Ratios
Emergent BioSolutions Inc, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
Emergent BioSolutions Inc, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021
Emergent BioSolutions Inc, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

★海外企業調査レポート[Emergent BioSolutions Inc (EBS):企業の財務・戦略的SWOT分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • TaiMed Biologics Inc (4147):製薬・医療:M&Aディール及び事業提携情報
    Summary TaiMed Biologics Inc (TMB) is a biotechnology company that provides novel medicines for the prevention and treatment of viral infectious diseases. The company provides pipeline products such as TMB-355, TMB-607 and TMB-571, among others. It offers TMB-355 which is a proprietary humanized ant …
  • AngioDynamics Inc (ANGO):医療機器:M&Aディール及び事業提携情報
    Summary AngioDynamics Inc (AngioDynamics) is a provider of minimally invasive medical, surgical and diagnostic devices. Its product portfolio encompasses peripheral vascular products, radiofrequency ablation and NanoKnife systems, vascular access products, angiographic products and accessories, prod …
  • Algonquin Power & Utilities Corp (AQN):電力:M&Aディール及び事業提携情報
    Summary Algonquin Power & Utilities Corp. (APUC) generates, transmits and distributes energy. It generates electricity through non-regulated renewable and clean energy and thermal generation facilities across North America. The company distributes electricity in California and New Hampshire; natural …
  • Stantec Inc (STN):企業の財務・戦略的SWOT分析
    Stantec Inc (STN) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the …
  • BWX Technologies Inc (BWXT):電力:M&Aディール及び事業提携情報
    Summary BWX Technologies Inc (BWXT) is a specialty manufacturer of nuclear components. It designs, engineers, and manufactures precision naval nuclear components, reactors, and nuclear fuel for the US Government. The company also provides special nuclear materials processing and environmental site r …
  • TechPrecision Corp (TPCS):企業の財務・戦略的SWOT分析
    Summary TechPrecision Corp (TechPrecision) is a diversified company. It offers vacuum chambers, pressure vessels, solar LED, nuclear lift equipment, and machinery. Its machinery includes petroleum by-product mixer, and polymer and chemical additive processing equipment. TechPrecision’s services comp …
  • Endesa SA (ELE):電力:M&Aディール及び事業提携情報
    Summary Endesa SA (Endesa), a subsidiary of Enel SpA, is an electric utility. It generates, distributes, and sells electricity. The company produces electricity in hydro, thermal, nuclear, combined cycle, and renewable and cogeneration plants. Endesa also supplies electricity and gas, and provides o …
  • Chemical Company of Malaysia Bhd (CCM):製薬・医療:M&Aディール及び事業提携情報
    Summary Chemical Company of Malaysia Bhd (CCM) is an industrial and specialty chemicals company. It manufactures and markets chlor-alkali and coagulant products; markets industrial and specialty chemicals; and produces polymer coating. The company’s chemical offerings find application in petrochemic …
  • National Electric Power Co:企業の戦略的SWOT分析
    National Electric Power Co - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products …
  • HiberGene Diagnostics Ltd:医療機器:M&Aディール及び事業提携情報
    Summary HiberGene Diagnostics Ltd (HiberGene Diagnostics) is a medical equipment company that manufactures, develops and markets molecular diagnostic tests for human infectious diseases using the LAMP technology. The company’s products include HG C. Difficile, HG Meningococcus, HG Group B Streptococ …
  • Schiller AG:企業の戦略的SWOT分析
    Schiller AG - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. …
  • Seikagaku Corp (4548):企業の財務・戦略的SWOT分析
    Summary Seikagaku Corp (Seikagaku) is a manufacturer and supplier of pharmaceuticals and medical devices. The company offers products such as pharmaceuticals and medical devices, bulk products, endotoxin-detecting reagents and oral care products. It also manufactures and markets pharmaceutical produ …
  • Entasis Therapeutics Inc-製薬・医療分野:企業M&A・提携分析
    Summary Entasis Therapeutics Inc (Entasis) discovers and develops anti-infective products for drug-resistant bacterial infections. The company’s pipeline products include ETX2514, a potent inhibitor of class A, C, and D beta-lactamases intended to treat serious gram-negative infections, such as Acin …
  • Price Forbes & Partners Ltd.:企業の戦略・SWOT・財務情報
    Price Forbes & Partners Ltd. - Strategy, SWOT and Corporate Finance Report Summary Price Forbes & Partners Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and s …
  • Central Bank Of India:企業の戦略・SWOT・財務分析
    Central Bank Of India - Strategy, SWOT and Corporate Finance Report Summary Central Bank Of India - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerin …
  • Vaxart Inc-製薬・医療分野:企業M&A・提携分析
    Summary Vaxart Inc (Vaxart) focuses on the development of recombinant vaccines based on its proprietary oral vaccine delivery platform. The company is currently developing tablet vaccines for seasonal and pandemic influenza, norovirus, and Respiratory Syncytial Virus (RSV). Vaxart’s vaccine delivery …
  • F-Secure Oyj (FSC1V):企業の財務・戦略的SWOT分析
    F-Secure Oyj (FSC1V) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …
  • NeuroMetrix Inc (NURO):医療機器:M&Aディール及び事業提携情報
    Summary NeuroMetrix Inc (NeuroMetrix) is a healthcare company company that develops wearable medical technology and point of care test to manage chronic pain, nerve diseases, and sleep disorders. The company’s products include quell wearable pain relief device, quell health cloud, DPNCheck point-of- …
  • Livzon Pharmaceutical Group Inc (000513):製薬・医療:M&Aディール及び事業提携情報
    Summary Livzon Pharmaceutical Group Inc (Livzon), a subsidiary of Joincare Pharmaceutical Group Industry Co Ltd, is a pharmaceutical company which is engaged in developing, manufacturing and distributing pharmaceutical products. The company provides preparation drug products, bulk medicines and inte …
  • Mithra Pharmaceuticals SA (MITRA):企業の財務・戦略的SWOT分析
    Summary Mithra Pharmaceuticals SA (Mithra) develops and manufactures over the counter products for women’s health and other applications. The company offers various drug products such as donesta, estelle, tibelia, myring, and zoreline. Its products are used in the treatment of contraception and fert …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆